Zynerba rises on positive long-term data from genetic disorder trial

Zynerba Pharmaceuticals

05/12/2022 17:19

** Shares of drug developer Zynerba Pharmaceuticals Inc
 ZYNE.O  rise 7.4% at 64 cents
    ** Co reports positive long-term data from mid-stage trial
treating Zygel in children and adolescents with 22q11.2 deletion
syndrome 
    ** 22q11.2 deletion syndrome, also known as DiGeorge
syndrome, is a condition in which a part of the chromosome 22 is
missing and can result in various developmental problems 
    ** Statistically significant improvements were seen on
long-term treatment with Zygel. The 38-week trial data continued
to show improvement in anxiety-related and behavioral symptoms -
Co 
    ** Co also says Zygel was generally well-tolerated, and the
safety profile was consistent with data from previous Zygel
clinical trials 
    ** Over the 38-week treatment period, three patients
reported mild application-site adverse events related to Zygel;
one patient discontinued treatment due to non-Zygel related
adverse events, says ZYNE
    ** ZYNE in October had reported positive data from the
treatment's mid-stage trial 
    ** Including session's gains, stock down 77.8% YTD
 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))